US Patent No: 6,461,641

Number of patents in Portfolio can not be more than 2000

Tumor delivery vehicles

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The major problem with current direct delivery techniques of therapeutic reagents into solid tumors, especially of cells or large volumes of recombinant DNA reagents or drugs, has been resistance of the tissues to the influx of the fluid and/or cells, resulting in low quantities of the fluid and/or cells penetrating into and remaining in the tumor tissue to be treated. Increased penetration and/or reduced backflow and diversion through the point of entry, so that more material is introduced into and remains in the tumor, is obtained through the use of a viscous vehicle, most preferably having a similar density to tissue, for the material to be delivered. Preferred materials include solutions or suspensions of a polymeric material which gel or solidify at the time of or shortly after injection or implantation. In the preferred embodiment, the solution is injected via a catheter into regions of the tumor to be treated.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
FBP CORPORATIONSAN FRANCISCO, CA2

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Fick, James R Martinez, GA 4 22

Cited Art

Patent Info (Count) # Cites Year
 
NEUROTECH USA, INC. (2)
5,656,481 Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsules 34 1995
6,027,721 Device and method for encapsulated gene therapy 5 1996
 
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (2)
4,868,116 Introduction and expression of foreign genetic material in epithelial cells 175 1986
4,980,286 In vivo introduction and expression of foreign genetic material in epithelial cells 236 1989
 
ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (1)
5,552,309 Use of polyols for improving the introduction of genetic material into cells 41 1994
 
ALLERGAN, INC. (1)
5,441,732 Reversible gelation emulsion compositions and methods of use 27 1992
 
COLD SPRING HARBOR LABORATORY (1)
5,674,703 Episomal vector systems and related methods 38 1993
 
FBP CORPORATION (1)
5,945,100 Tumor delivery vehicles 15 1996
 
HIMMELSTEIN, KENNETH J. (1)
5,599,534 Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use 21 1994
 
MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (1)
6,096,303 Method to enhance treatment of cystic tumors 5 1997
 
PHARMACEUTICAL DISCOVERY CORPORATION (1)
6,071,497 Microparticles for lung delivery comprising diketopiperazine 84 1997
 
REPLIGEN CORPORATION (1)
4,352,883 Encapsulation of biological material 406 1979
 
STEWARD RESEARCH AND SPECIALTY PROJECTS CORPORATION (1)
5,652,225 Methods and products for nucleic acid delivery 69 1996
 
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (1)
5,763,416 Gene transfer into bone cells and tissues 79 1994
 
YALE UNIVERSITY (1)
6,090,784 RNA polymerase II peptides and methods of use 2 1995

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO—FAPESP (1)
8,278,265 Methods, kits and compositions comprising crotamine 0 2007
 
TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (1)
8,391,959 Composition for improving efficiency of drug delivery 0 2005

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 8, 2014
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00